These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33279285)

  • 1. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy.
    Yavuz S; Balsak S; Karahan M; Dursun B
    J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy.
    Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q
    Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy.
    Han JY; Kim YJ; Choi EY; Lee J; Lee JH; Kim M; Byeon SH; Kim SS; Lee CS
    Yonsei Med J; 2022 Apr; 63(4):365-371. PubMed ID: 35352888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy.
    Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F
    Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Lee JH; Lee SC; Kim H; Lee CS
    Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study.
    Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S
    Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
    Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
    Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Kim DY; Lee JY; Lee EK; Kim JY
    Retina; 2020 Jun; 40(6):1191-1199. PubMed ID: 30897068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone in the treatment of central serous chorioretinopathy - a case series.
    Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Mineralocorticoid-Receptor Antagonists: Choroidal Parameters Changes Using OCT in Central Serous Chorioretinopathy.
    Faghihi H; Mohammadzadeh V; Nabavi A; Faghihi S; Kadivar S; Ghassemi F
    Ophthalmic Surg Lasers Imaging Retina; 2019 Nov; 50(11):726-733. PubMed ID: 31755972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
    Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
    Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
    Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
    Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy.
    Falavarjani KG; Amirsardari A; Habibi A; Eshaghi A; Bakhti S; Aghdam KA
    J Ophthalmic Vis Res; 2017; 12(3):281-289. PubMed ID: 28791061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy.
    An SH; Kwon YH
    Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1489-1496. PubMed ID: 26553195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone for treatment of chronic central serous chorioretinopathy.
    Fraenkel D; Suffo S; Langenbucher A; Seitz B; Abdin AD
    Eur J Ophthalmol; 2021 Jul; 31(4):1885-1891. PubMed ID: 32854564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
    Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
    Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
    Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in Nonresolving Central Serous Chorioretinopathy.
    Bousquet E; Dhundass M; Lejoyeux R; Shinojima A; Krivosic V; Mrejen S; Gaudric A; Tadayoni R
    Am J Ophthalmol; 2019 Feb; 198():80-87. PubMed ID: 30308202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal retinal imaging in central serous chorioretinopathy treated with oral eplerenone or photodynamic therapy.
    Rabiolo A; Zucchiatti I; Marchese A; Baldin G; Sacconi R; Montorio D; Cicinelli MV; Querques L; Bandello F; Querques G;
    Eye (Lond); 2018 Jan; 32(1):55-66. PubMed ID: 29265111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.